Neurogenic Bladder: Epidemiology, Diagnosis, and Management

Jalesh N Panicker, Jalesh N Panicker

Abstract

Lower urinary tract dysfunction is a common sequel of neurological disease resulting in symptoms that significantly impacts quality of life. The site of the neurological lesion and its nature influence the pattern of dysfunction. The risk for developing upper urinary tract damage and renal failure is considerably lower in patients with slowly progressive nontraumatic neurological disorders, compared with those with spinal cord injury or spina bifida. This acknowledged difference in morbidity is considered when developing appropriate management algorithms. The preliminary evaluation consists of history taking, and a bladder diary and may be supplemented by tests such as uroflowmetry, post-void residual measurement, renal ultrasound, (video-)urodynamics, neurophysiology, and urethrocystoscopy, depending on the clinical indications. Incomplete bladder emptying is most often managed by intermittent catheterization, and storage dysfunction is managed by antimuscarinic medications. Intra-detrusor injections of onabotulinumtoxinA have revolutionized the management of neurogenic detrusor overactivity. Neuromodulation offers promise for managing both storage and voiding dysfunction. In select patients, reconstructive urological surgery may become necessary. An individualized, patient-tailored approach is required for the management of lower urinary tract dysfunction in this special population.

Conflict of interest statement

J.N.P. reports other from Wellspect, Astellas, and from Novartis and grants from Parkinson's UK and Cambridge University Press, outside the submitted work.

Thieme. All rights reserved.

Figures

Fig. 1
Fig. 1
The pattern of lower urinary tract dysfunction following neurological disease is influenced by the site of lesion. PVR, post-void residual. (Used with permission from Panicker et al. 5 )
Fig. 2
Fig. 2
Two types of afferent nerves convey sensations of bladder filling. (A) In health, thinly myelinated Ad fibers have a lower threshold for activation and are responsible for conveying sensations of bladder filling, whereas unmyelinated C-fibers have a greater threshold for activation and are thought to be quiescent. (B) Following spinal cord damage, C-fibers become sensitized and are mechanosensitive at lower bladder volumes. A segmental spinal reflex emerges that is mediated by C-fibers afferents nerves and results in involuntary detrusor contractions, the basis for NDO. LUT, lower urinary tract; NDO, neurogenic detrusor overactivity. (Used with permission from Panicker et al. 7 )

References

    1. Fowler C J, Griffiths D, de Groat W C. The neural control of micturition. Nat Rev Neurosci. 2008;9(06):453–466.
    1. Fowler C J. Integrated control of lower urinary tract–clinical perspective. Br J Pharmacol. 2006;147 02:S14–S24.
    1. Griffiths D J. The pontine micturition centres. Scand J Urol Nephrol Suppl. 2002;(210):21–26.
    1. Michels L, Blok B F, Gregorini F. Supraspinal control of urine storage and micturition in men–an fMRI study. Cereb Cortex. 2015;25(10):3369–3380.
    1. Panicker J N, Fowler C J, Kessler T M. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(07):720–732.
    1. de Groat W C.A neurologic basis for the overactive bladder Urology 199750(6A, Suppl): discussion 53–5636–52.
    1. Panicker J N, Seth J H. C-fibre sensory nerves - not so silent as we think? BJU Int. 2013;112(01):129–130.
    1. de Groat W C, Kawatani M, Hisamitsu T.Mechanisms underlying the recovery of urinary bladder function following spinal cord injury J Auton Nerv Syst 199030(Suppl):S71–S77.
    1. Martinez-Martin P, Schapira A H, Stocchi F. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22(11):1623–1629.
    1. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff J M, Giladi N. Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol. 2005;252(11):1310–1315.
    1. McGrother C W, Jagger C, Clarke M, Castleden C M. Handicaps associated with incontinence: implications for management. J Epidemiol Community Health. 1990;44(03):246–248.
    1. Smith M, Seth J, Batla A, Hofereiter J, Bhatia K P, Panicker J N. Nocturia in patients with Parkinson's disease. Mov Disord Clin Pract (Hoboken) 2015;3(02):168–172.
    1. Parkinson's Disease Subcommittee, The Neurourology Promotion Committee in The International Continence Society . Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn. 2016;35(05):551–563.
    1. Sakakibara R, Panicker J, Simeoni S. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res. 2019;29(06):627–631.
    1. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord. 2010;25(01):2–12.
    1. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001;71(05):600–606.
    1. Sakakibara R, Kanda T, Sekido T. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn. 2008;27(06):507–510.
    1. Ransmayr G N, Holliger S, Schletterer K. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70(04):299–303.
    1. Sink K M, Thomas J, III, Xu H, Craig B, Kritchevsky S, Sands L P. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(05):847–853.
    1. Han K S, Heo S H, Lee S J, Jeon S H, Yoo K H. Comparison of urodynamics between ischemic and hemorrhagic stroke patients; can we suggest the category of urinary dysfunction in patients with cerebrovascular accident according to type of stroke? Neurourol Urodyn. 2010;29(03):387–390.
    1. Kuchel G A, Moscufo N, Guttmann C R. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2009;64(08):902–909.
    1. Tadic S D, Griffiths D, Murrin A, Schaefer W, Aizenstein H J, Resnick N M. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. Neuroimage. 2010;51(04):1294–1302.
    1. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci. 1996;137(01):47–56.
    1. GENULF . de Sèze M, Ruffion A, Denys P, Joseph P A, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(07):915–928.
    1. Mahajan S T, Patel P B, Marrie R A. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010;183(04):1432–1437.
    1. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671–676.
    1. Phé V, Chartier-Kastler E, Panicker J N. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(05):275–288.
    1. Blok B, Pannek J, Castro-Diaz D. European Association of Urology; 2015. Guidelines on Neuro-Urology.
    1. Podnar S, Fowler C. Cambridge: Cambridge University Press; 2010. Pelvic organ dysfunction following cauda equina damage.
    1. Smith M D, Seth J H, Fowler C J, Miller R F, Panicker J N. Urinary retention for the neurologist. Pract Neurol. 2013;13(05):288–291.
    1. Panicker J N, Game X, Khan S. The possible role of opiates in women with chronic urinary retention: observations from a prospective clinical study. J Urol. 2012;188(02):480–484.
    1. Datta S N, Chaliha C, Singh A. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int. 2008;101(02):192–196.
    1. Panicker J N, Seth J H, Khan S. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome) BJU Int. 2016;117(05):809–813.
    1. Lawrenson R, Wyndaele J J, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology. 2001;20(02):138–143.
    1. Castel-Lacanal E, Gamé X, Clanet M. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurourol Urodyn. 2015;34(01):32–36.
    1. Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira M C. Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord. 2012;50(07):558–562.
    1. Kessler T M.Diagnosis of urinary incontinence JAMA 200830003283, author reply 283
    1. NICE . Urinary incontinence in neurological disease: assessment and management. Clinical guideline (CG148) 2012.
    1. Fowler C J, Panicker J N, Drake M. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(05):470–477.
    1. Podnar S, Trsinar B, Vodusek D B. Bladder dysfunction in patients with cauda equina lesions. Neurourol Urodyn. 2006;25(01):23–31.
    1. Palace J, Chandiramani V A, Fowler C J. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve. 1997;20(11):1396–1403.
    1. Panicker J, DasGupta R, Elneil S. Cambridge: Cambridge University Press; 2010. Urinary retention.
    1. Palma J A, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(03):372–390.
    1. Gajewski J B, Awad S A. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol. 1986;135(05):966–968.
    1. Propiverine Investigator Group . Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold E P, Wyndaele J J. Propiverine compared to oxybutynin in neurogenic detrusor overactivity–results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007;51(01):235–242.
    1. Mazo E B, Babanina G A. [Trospium chloride (Spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions] Urologiia. 2007;(03):15–19.
    1. Ethans K D, Nance P W, Bard R J, Casey A R, Schryvers O I. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27(03):214–218.
    1. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753.
    1. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62(05):816–830.
    1. Buser N, Ivic S, Kessler T M, Kessels A G, Bachmann L M. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62(06):1040–1060.
    1. Gray S L, Anderson M L, Dublin S. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(03):401–407.
    1. Alzheimer's Disease Neuroimaging Initiative . Risacher S L, McDonald B C, Tallman E F. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(06):721–732.
    1. Fox C, Smith T, Maidment I. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(05):604–615.
    1. Davis T P, Sanchez-Covarubias L, Tome M E. P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. Adv Pharmacol. 2014;71:25–44.
    1. Chancellor M B, Staskin D R, Kay G G, Sandage B W, Oefelein M G, Tsao J W. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(04):259–273.
    1. Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(09):1279–1286.
    1. Isik A T, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging. 2009;13(08):672–676.
    1. Chapple C R, Cardozo L, Nitti V W, Siddiqui E, Michel M C. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(01):17–30.
    1. Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37(08):2810–2817.
    1. Peyronnet B, Vurture G, Palma J A. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018;57:22–26.
    1. Krhut J, Borovička V, Bílková K. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity—prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(07):2226–2233.
    1. Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(01):1–5.
    1. Schurch B, Stöhrer M, Kramer G, Schmid D M, Gaul G, Hauri D.Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 2000164(3, Pt 1):692–697.
    1. Schurch B, Schmid D M, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(09):665.
    1. Cruz F, Herschorn S, Aliotta P. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(04):742–750.
    1. Ginsberg D, Gousse A, Keppenne V. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(06):2131–2139.
    1. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(03):705–711.
    1. Kennelly M, Dmochowski R, Ethans K. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(03):491–497.
    1. Peters K M, Carrico D J, Perez-Marrero R A. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(04):1438–1443.
    1. Kabay S C, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn. 2009;28(01):62–67.
    1. Kabay S, Kabay S C, Yucel M. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(08):964–968.
    1. Gobbi C, Digesu G A, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler. 2011;17(12):1514–1519.
    1. Salatzki J, Liechti M D, Spanudakis E.Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder BJU Int 2019123(5A):E20–E28.
    1. de Sèze M, Raibaut P, Gallien P. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(03):306–311.
    1. Monteiro E S, de Carvalho L B, Fukujima M M, Lora M I, do Prado G F. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology. 2014;84(03):509–514.
    1. Phé V, Pakzad M, Curtis C. Urinary tract infections in multiple sclerosis. Mult Scler. 2016;22(07):855–861.
    1. Seth J H, Haslam C, Panicker J N. Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence. 2014;8:191–198.
    1. Prasad R S, Smith S J, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(01):42–47.
    1. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Naumann M, So Y, Argoff C E. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707–1714.
    1. Phé V, Pakzad M, Haslam C. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn. 2017;36(07):1770–1775.
    1. Gallien P, Amarenco G, Benoit N. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler. 2014;20(09):1252–1259.

Source: PubMed

3
Iratkozz fel